The market for anti-diarrhea medicine drugs is up more than 400 percent in 2017 compared with 2016.
The rise has been driven in large part by President Donald Trump’s Twitter feed, which has become a source of information for the pharmaceutical industry.
“The surge in demand for anti diphtheria drugs is a testament to the president’s relentless media blitzes, especially on social media,” said David J. Bialek, president of the trade association for the Pharmaceutical Research and Manufacturers of America.
“The Trump administration is using his tweets to promote and sell anti dibs, and the volume is likely to continue to grow as demand grows.”
Anti-dibs are made from a derivative of the bacterium diphtherophagia, a form of the bacteria that causes diphritis, an infection that leads to fever and abdominal pain.
The drug is typically given as a pill or a shot, and is sometimes given in a shot.
The surge was driven by Trump’s tweets in late January and early February, which focused on the opioid crisis.
“As the U.S. begins a new era, it is critical that we keep focused on preventing the spread of drug-resistant superbugs and ending the epidemic of opioid abuse,” Trump tweeted.
“If we don’t do our part, our loved ones and communities will continue to die.”
A spokesperson for Pfizer, the maker of the drug, did not respond to a request for comment.
The White House is trying to capitalize on the popularity of anti-dipophosphonate (DIP) antibiotics, which have been used to treat urinary tract infections and bacterial infections in both adults and children.
The president has also been encouraging the use of anti DIP drugs.
In early February he tweeted, “The DIP-A has surpassed DIP as the most popular antibiotic on the market.
It is only a matter of time until the DIPA hits the shelves.”
The increase in demand has been fueled by the Trump administration’s Twitter feeds.
In late January, the president tweeted, “[W]e have more DIPs on the shelf than we have in years.
The market is surging!”
The rise in demand was fueled by Trump tweeting about the opioid epidemic.
In early February the president also tweeted, “(W)e have been using the DPI-A to treat UTIs for decades.
We have a great track record.
And now it’s getting a little bit better.”
In an interview with ABC News in early February , Dr. Jonathan Schanzer, a professor of microbiology at the University of California, Los Angeles, said, “I think the President’s tweets are driving the demand for DIP.”
“He is making the case to patients that DIP is the way to go,” Schanster said.
“He is telling patients that they can have this for a long time.”